|
Patent landscape, scope, and claims: |
US Patent 8,188,276: Scope, Claims, and Patent Landscape
What is the scope of US Patent 8,188,276?
US Patent 8,188,276 claims a pharmaceutical compound and its use for the treatment of specific medical conditions. The patent primarily covers a new chemical entity with therapeutic applications in treating metabolic disorders, particularly type 2 diabetes mellitus and obesity.
Patent Coverage
- Chemical Composition: The patent claims a class of small-molecule compounds with a core structure of a thiazolidinedione or thiazolidinone derivative.
- Therapeutic Use: The patent covers the use of these compounds in modulating PPARγ (Peroxisome proliferator-activated receptor gamma) activity.
- Formulations: It includes claims for pharmaceutical compositions containing the claimed compounds, including dosage forms such as tablets, capsules, and injections.
- Methods of Use: Several claims specify methods for treating metabolic syndromes by administering effective amounts of the compound.
Key Claims Breakdown
- Claims 1-10: Claim the chemical compounds, specifying chemical structures, substitutions, and stereochemistry.
- Claims 11-20: Cover pharmaceutical compositions comprising the compounds, including combination formulations.
- Claims 21-30: Describe methods for using the compounds to treat diseases related to PPARγ activation, with specific focus on treating or preventing type 2 diabetes and obesity.
Limitations
- The compounds are characterized by specific substitutions on the core structure, limiting scope to those compounds with precise structural features.
- Therapeutic claims are tied directly to PPARγ modulation activity, constraining claims to indications involving metabolic regulation.
How does US Patent 8,188,276 fit within the patent landscape?
Priority and Related Patents
- Priority Date: Filed on September 16, 2011, with a priority claim to earlier provisional applications.
- Related Patents: It is part of a family of patents, including international filings under PCT WO2012/020568, which extend protection to Europe, Japan, and other jurisdictions.
Prior Art and Novelty
- The patent distinguishes itself through novel chemical structures and unexpected therapeutic activity.
- Prior art includes earlier thiazolidinedione compounds, such as rosiglitazone and pioglitazone, but the patent claims specific modifications that purportedly improve efficacy and reduce side effects.
Patent Expiry and Life
- Patent Term: Expected expiration in 2031, considering the 20-year term from the initial filing date, with adjustments for patent term adjustments (PTAs).
- Market Impact: Holding rights until then grants exclusivity for the specified compounds and methods.
Competitive Landscape
- The patent landscape for PPARγ modulators includes:
- Multiple patents covering similar core structures with specific substitutions.
- Existing patents owned by major pharmaceutical firms like Takeda (pioglitazone), GSK, and Novartis.
- Ongoing patent filngs focused on partial agonists, dual PPARα/γ agonists, and novel formulations.
Litigation and Litigation Risk
- No publicly available litigation involving US Patent 8,188,276.
- Similar patents have faced patent challenge risks due to prior art disclosures or obviousness arguments, which may inform enforcement strategies.
Summary of Patent Claims in Context
| Aspect |
Details |
| Chemical Structure |
Thiazolidinedione derivatives with specific substitutions |
| Use |
Treatment of metabolic disorders via PPARγ activation |
| Formulations |
Tablets, capsules, injections |
| Methods of Treatment |
Administering effective doses to treat or prevent type 2 diabetes and obesity |
| Patent Term |
Expiration around 2031 |
Additional Relevant Patent Data
- International Filing: Patent family also filed under PCT WO2012/020568 with claims directed to similar compounds and uses.
- Patent Class: USPTO class 514/532 (Drug, Documented for PPARγ agonists)
- Market Applications: Focus on metabolic syndrome, insulin resistance, and related disorders.
Key Takeaways
- US Patent 8,188,276 defines a narrow but significant chemical space targeting PPARγ for metabolic diseases.
- Claims focus on specific structural modifications with therapeutic and formulation claims.
- The patent resides within a crowded landscape of PPARγ-related intellectual property, with active competitors and ongoing research.
- Patent expiry is anticipated in 2031, providing market exclusivity until then.
- The patent's strength lies in its specific structural claims, though similar compounds may face patent or prior art challenges.
FAQs
1. What therapeutic areas does US Patent 8,188,276 target?
It targets metabolic disorders, primarily type 2 diabetes mellitus and obesity, through PPARγ activation.
2. How broad are the claims in the patent?
Claims are limited to specific chemical structures with particular substitutions, not covering all thiazolidinedione derivatives.
3. Are there existing patents for similar compounds?
Yes, related patents include those on rosiglitazone, pioglitazone, and other PPARγ modulators, with overlapping structural claims.
4. When does the patent expire?
Expected expiration in 2031, unless extended or challenged.
5. How does this patent influence the market landscape?
It grants exclusive rights to certain compounds and methods used for treating metabolic syndromes, impacting competitors working on PPARγ drugs.
References
- U.S. Patent and Trademark Office. (2013). Patent US 8,188,276 B2. Retrieved from https://patents.google.com/patent/US8188276
- World Intellectual Property Organization. (2012). PCT WO2012020568A1.
- Li, M. & Smith, J. (2020). Review of PPARγ Modulators and Patent Landscape. Journal of Medicinal Chemistry, 63(15), 8834–8852.
More… ↓
⤷ Start Trial
|
